Academic Journal
Validity of self-reported use of antihypertensives and lipid modifying agents: Results from the population-based HUNT Study.
| Τίτλος: | Validity of self-reported use of antihypertensives and lipid modifying agents: Results from the population-based HUNT Study. |
|---|---|
| Συγγραφείς: | Olsen KS; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway., Hallan SI; Department of Nephrology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Selbæk G; Norwegian Centre for Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway; Faculty of Medicine, University of Oslo, Norway; Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway., Næss M; HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Krokstad S; HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Holmen J; HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway., Ernstsen L; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. Electronic address: linda.ernstsen@ntnu.no. |
| Πηγή: | Annals of epidemiology [Ann Epidemiol] 2026 Aug; Vol. 120, pp. 110122. Date of Electronic Publication: 2026 May 22. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: United States NLM ID: 9100013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2585 (Electronic) Linking ISSN: 10472797 NLM ISO Abbreviation: Ann Epidemiol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Elsevier, c1990- |
| Ιατρικοί όροι (MeSH): | Antihypertensive Agents*/therapeutic use , Hypolipidemic Agents*/therapeutic use , Self Report*/standards , Hypertension*/drug therapy , Cardiovascular Diseases*/prevention & control , Cardiovascular Diseases*/drug therapy, Norway/epidemiology ; Humans ; Female ; Cross-Sectional Studies ; Male ; Aged ; Middle Aged ; Reproducibility of Results ; Sensitivity and Specificity ; Cognition ; Adult |
| Περίληψη: | Background: Cardiovascular disease is a major global health burden, emphasizing the importance of blood pressure medications and lipid-modifying agents in prevention and treatment. Accurate self-reported data on the use of these drugs are vital for epidemiological research, yet the influence of age, sex, and cognitive function on reporting validity is not well understood. This study assesses self-reported use of these two drug classes within a large population-based Norwegian cohort and examines how demographic and cognitive factors affect reporting accuracy. Methods: Cross-sectional study using data on self-reported medication use in the fourth wave of the population-based Trøndelag Health Study (HUNT4, 2017-19). Sensitivity, specificity and Cohen´s Kappa Statistics were calculated to assess accuracy using the Norwegian Prescribed Drug Registry as the gold standard. Analyses were stratified by age and sex, and by cognitive function for participants aged 70 years or older in the substudy HUNT4 70 + . Results: A total of 55,086 participants (54.3% women) were included in this study, and the mean age (SD) was 54.0 (17.4) years. Out of these, 8762 also participated in the substudy HUNT4 70 + (2017-2019), where 3132 participants had mild cognitive impairment and 779 had dementia. In the total sample, sensitivity and specificity were > 90% for both blood pressure medication and lipid-modifying agents. Kappa statistics indicated substantial agreement for blood pressure medication (0.74-0.79), and substantial to almost perfect agreement for lipid-modifying agents (0.79-0.81). Agreement was highest among middle-aged participants and lower in the oldest. Chi-square tests revealed significant sex differences for both medication groups (p < 0.001), demonstrating higher agreement among women. Furthermore, cognitive function was strongly associated with reporting accuracy, with the highest agreement among cognitively healthy participants. Conclusion: Self-reported data on the use of blood pressure medication and lipid-modifying agents were highly reliable. However, agreement was influenced by age, sex, and cognitive function. (Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Competing Interests: | Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kjerstin Solstad Olsen reports financial support was provided by Research Council of Norway. Linda Ernstsen reports article publishing charges was provided by Norwegian University of Science and Technology. Geir Selbæk has participated in Advisory Board meetings for Roche, Eli-Lilly and Eisai regarding disease-modifying drugs for Alzheimer’s disease. Geir Selbæk has received honoraria for delivering lectures at symposia sponsored by Eisai and Eli-Lilly. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Blood pressure medication; Cognition; Drug prescriptions; Hypolipidemic agents; Registries; Self report; Sex factors |
| Substance Nomenclature: | 0 (Antihypertensive Agents) 0 (Hypolipidemic Agents) |
| Entry Date(s): | Date Created: 20260523 Date Completed: 20260612 Latest Revision: 20260612 |
| Update Code: | 20260613 |
| DOI: | 10.1016/j.annepidem.2026.110122 |
| PMID: | 42176715 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-2585 |
|---|---|
| DOI: | 10.1016/j.annepidem.2026.110122 |